澳大利亚和新西兰透析与移植登记中钙化防御发作分析
该研究基于ANZDATA登记,分析2019至2022年接受肾脏替代治疗(KRT)患者的钙化防御发作。透析患者钙化防御发生率为4.5/1000患者年,诊断后12个月内半数死亡,调整后1年内死亡HR达5.8。
要点
- 透析患者钙化防御发生率4.5/1000患者年,诊断后12个月内半数死亡。
- 钙化防御患者多高龄、女性、糖尿病、肥胖,常合并冠脉及外周血管病。
核心结论
- 钙化防御在KRT患者中罕见但危及生命,诊断后12个月内死亡负担最重。
研究设计与样本
- 回顾性队列研究,纳入2019至2022年ANZDATA登记的KRT患者,比较钙化防御患者与无钙化防御患者。
主要发现
- 透析患者钙化防御发生率为4.5(4.1-5.1)例/1000患者年。
- 钙化防御患者中位年龄63岁,54%女性,66%糖尿病,59%肥胖,77%接受血液透析。
- 钙化防御诊断后12个月内半数患者死亡。
- 透析患者钙化防御后<1年死亡调整HR为5.8(4.9-6.9),1-4年为1.5(1.0-2.1)。
- 钙化防御中位发生时间为KRT开始后3.2年。
临床怎么用
- 对KRT患者应警惕钙化防御,尤其高龄、女性、糖尿病、肥胖及血管疾病者。
- 钙化防御诊断后第一年死亡率极高,需加强监测与综合管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Calciphylaxis is a rare disorder associated with significant morbidity and mortality. Data registries are an invaluable source of information for rare diseases. We reviewed cases of calciphylaxis recorded in the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) and evaluated associations and outcomes of this condition. METHODS: Data was obtained on all cases of calciphylaxis reported between 2019 and 2022 in Australian and New Zealand patients on kidney replacement therapy (KRT). This cohort was compared to all patients in the registry who received KRT from 2019 to 2022 without an episode of calciphylaxis. Cox proportional hazards regression including a time-varying covariate for calciphylaxis episode was conducted for mortality with models restricted to patients on dialysis only. RESULTS: From 2019 to 2022, 333 patients had calciphylaxis episodes reported. Overall incidence rate for patients on dialysis was 4.5 (4.1-5.1) episodes per 1000 patient-years on dialysis. Median age was 63 (interquartile range [IQR]: 55-73) years, 54% were female, 66% had diabetes, 59% were obese (body mass index [BMI] ≥ 30 kg/m2) and 77% were receiving hemodialysis (HD) treatment. Compared to patients without calciphylaxis (n = 46,526), patients with calciphylaxis were more likely to be older, female, and have diabetes, greater BMI, coronary artery, and peripheral vascular disease. The median time to calciphylaxis was 3.2 (IQR: 0.9-6.7) years after KRT commencement. Half of the patients with calciphylaxis died by 12 months from diagnosis. Adjusted hazard ratio (HR) of mortality for patients on dialysis with calciphylaxis <1 year and 1 to 4 years after an episode was 5.8 (4.9-6.9) and 1.5 (1.0-2.1), respectively compared to patients on dialysis without calciphylaxis. CONCLUSION: Calciphylaxis is a rare but life-threatening condition in people on KRT with the greatest mortality burden within 12 months of diagnosis.
引用
- Toussaint ND, Davies CE, Bongetti E, et al. Calciphylaxis Episodes in the Australia and New Zealand Dialysis and Transplant Registry. Kidney Int Rep. 2024. PMID: 38765561. doi:10.1016/j.ekir.2024.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。